CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia

Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.

Authors

Wendy Stock (ORCID: https://orcid.org/0000-0002-8349-9200)
Sandeep Gurbuxani (ORCID: https://orcid.org/0000-0003-0716-8730)
Ryan W. Hunter (ORCID: https://orcid.org/0000-0002-0422-2570)
Hamed Rahmani Youshanlouei (ORCID: https://orcid.org/0000-0003-0263-8895)
Anand Patel (ORCID: https://orcid.org/0000-0002-0296-8686)
Rafael Madero‐Marroquin (ORCID: https://orcid.org/0009-0002-9243-2662)
Hannah Johnston
Adam DuVall (ORCID: https://orcid.org/0000-0002-9163-8792)
Clinton Osei
Caner Saygin (ORCID: https://orcid.org/0000-0003-1315-0377)
Syed Shah (ORCID: https://orcid.org/0000-0003-4992-934X)